Capital Markets Day: Commercial Execution and Innovation in Obesity Care
17
Commercial execution and innovation
Obesity care
Novo NordiskⓇ
In IO, Obesity care sales will continue to be mostly out of pocket,
but reimbursement is improving
The majority of SaxendaⓇ sales are
out of pocket
Restricted reimbursement for SaxendaⓇ is
progressing
(examples)
80%
Out of pocket sales
20%
Restricted reimbursement sales
✡
BMI>30
with one co-morbidity
BMI >30
with 50% co-pay after 2 dietician
visits
BMI>35
With pre-diabetes and risk of CV
Focus will be to increase innovation
accessibility and improve reimbursement
Saxenda
liraglutide injection
Continue launches and bring innovation
ONCE-WEEKLY
wegovy®
semaglutide injection 2.4 mg
Improve reimbursement via cost
effectiveness analysis and innovative
contracting
SELECT
semaglutide effects on cardiovascular
outcomes in people with overweight or obesity
Of the 15 countries with restricted
reimbursement for SaxendaⓇ 8 have come
in the last 2 years
Further evidence via SELECT and health
economics data
Restricted reimbursed countries include: Iceland, Norway, Switzerland, United Kingdom, Luxembourg, Sweden, Belgium, Denmark, Finland, Ireland, Colombia, Netherlands, Israel, Turkey and Qatar
IO: International Operations; BMI: Body mass index
CMD22
CAPITAL MARKETS DAYView entire presentation